Equillium Reports Third Quarter 2026 Financial Results and Recent Corporate and Clinical Highlights
First participant dosed in Phase 1 clinical trial of EQ504, proof-of-mechanism data expected in Q2 2
First participant dosed in Phase 1 clinical trial of EQ504, proof-of-mechanism data expected in Q2 2